vTv Therapeutics (NASDAQ:VTVT) Stock Crosses Below 50 Day Moving Average – Here’s What Happened

vTv Therapeutics Inc. (NASDAQ:VTVT) crossed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $33.93 and traded as low as $33.21. vTv Therapeutics shares last traded at $35.08, with a volume of 94,154 shares trading hands.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the stock. Zacks Research cut shares of vTv Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, June 11th. Wall Street Zen upgraded shares of vTv Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. Weiss Ratings raised vTv Therapeutics from a “sell (d-)” rating to a “sell (d+)” rating in a research report on Monday, May 18th. Evercore initiated coverage on vTv Therapeutics in a research note on Thursday, March 12th. They issued an “outperform” rating and a $44.00 price target on the stock. Finally, BTIG Research reaffirmed a “buy” rating and set a $49.00 price objective on shares of vTv Therapeutics in a research report on Wednesday, March 11th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $53.00.

vTv Therapeutics Stock Performance

The company has a market capitalization of $138.22 million, a PE ratio of -37.72 and a beta of 0.27. The company’s 50-day moving average is $33.93 and its 200 day moving average is $35.59.

vTv Therapeutics (NASDAQ:VTVT) last issued its earnings results on Wednesday, May 13th. The biotechnology company reported $1.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.21 by $1.44. The firm had revenue of $36.84 million during the quarter, compared to the consensus estimate of $20.00 million. On average, analysts forecast that vTv Therapeutics Inc. will post -2.19 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Baker BROS. Advisors LP boosted its position in shares of vTv Therapeutics by 52.4% during the third quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company’s stock valued at $3,463,000 after buying an additional 51,000 shares during the last quarter. Geode Capital Management LLC raised its position in vTv Therapeutics by 84.3% in the 4th quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock worth $1,128,000 after buying an additional 12,896 shares during the last quarter. Goldman Sachs Group Inc. bought a new position in vTv Therapeutics during the 4th quarter valued at about $221,000. Finally, 683 Capital Management LLC purchased a new stake in shares of vTv Therapeutics during the 4th quarter valued at about $731,000. Hedge funds and other institutional investors own 17.51% of the company’s stock.

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.